AARD - Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
As of May 15, 2026: spot at $4.62, ATM IV 21.2%, net GEX -$6.4K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $143.8M
- Beta
- 5.11
- 52-Week Range
- 3.35-17.94
- CEO
- Tien-Li Lee
- Employees
- 22
- IPO Date
- Feb 13, 2025
- Exchange
- NASDAQ
What AARD Looks Like to Options Traders Today
negative net gamma exposure (-$6.4K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves.
What This Page Covers
The AARD overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked AARD overview questions
- What is AARD?
- AARD is the ticker symbol for Aardvark Therapeutics, Inc. Common Stock, a listed security. Aardvark Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Listed on NASDAQ. AARD is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the AARD options snapshot look like today?
- As of May 15, 2026, the AARD options snapshot shows spot at $4.62, ATM IV 21.2%, net GEX -$6.4K, expected move 6.08%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are AARD's key statistics?
- Aardvark Therapeutics, Inc. Common Stock (AARD) carries a market capitalization of $143.8M, beta of 5.11 relative to the broader market, 52-week range of 3.35-17.94. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does AARD belong to?
- Aardvark Therapeutics, Inc. Common Stock operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare AARD's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the AARD data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).